Multi-target immune cell therapy for acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy that uses your own cells, modified to attack leukemia cells in multiple ways. It aims to find a safe and effective dose for people with acute myeloid leukemia who have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 2 years.
- Your leukemia cells must show certain markers (like CD33, CD123) that the therapy targets.
- You should be physically active and able to care for yourself (Karnofsky score above 80).
- Your heart, lungs, liver, and kidneys must be working well enough (checked by tests).
- You must not have serious infections, HIV, or hepatitis B.
- You cannot be pregnant or breastfeeding, and you must not have had gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a universal CAR-T cell therapy for acute myeloid leukemia (AML), a type of blood cancer. The treatment uses specially engineered immune cells to target leukemia cells with certain markers, and the trial aims to see if it is safe and effective for patients whose leukemia has not responded to standard treatments.
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
This trial tests an experimental treatment using your own immune cells (called CAR-T cells) that are specially designed to find and destroy leukemia cells that have a specific marker called CD123. It is for people with acute myeloid leukemia (AML) that has not responded to treatment or has returned, and who have limited other options.
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
This trial tests a new type of immune cell therapy (called iNKT cells) that is designed to find and attack leukemia cells. It's for people whose leukemia has come back or hasn't gone away after standard treatments. The goal is to see if this therapy is safe and can help.
This trial tests a personalized cell therapy that uses your own immune cells (T cells) to target a specific protein (AML1-ETO) found in certain AML cells. It is for patients whose leukemia has come back or not gone away after standard treatment.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.